ASTRAZENECA PLC
AZN · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $185.78 — last insider sale, 2026-05-20 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
A87Dominant global pharma franchise with a deep patent-protected oncology/biopharma portfolio, top-decile returns and elite cash generation.
Strengths
- Top-decile operating margin 23.4% (92nd pct), ROA 9% (91st), ROIC 13.9% (91st), FCF $11.8B (99th pct)
- ROE 21% (82nd pct) with +45% net income growth and 82% gross margin; durable IP moat across multiple blockbusters
- Scaled, diversified revenue base ($55B product sales) growing high single digits
Risks
- Patent cliffs (e.g., Tagrisso, Soliris erosion) and IRA/JCA pricing pressure
- Low current/quick ratio (15th/14th pct) and moderate leverage (D/E 0.61)
Notable findings
- Weak liquidityCurrent ratio 0.94 (<1)
- Strong balance sheetStrong balance sheet — $5.7B cash & investments
- Insider sellingInsider selling — 1 open-market sale(s) by 1 insider(s) (~$2M, last 6mo) Form 4 ↗
Key metrics
Gross margin
81.9%
Operating margin
23.4%
Net margin
17.4%
Return on equity
21.0%
Return on assets
9.0%
ROIC
13.9%
Revenue growth (QoQ)
8.6%
Net-income growth
45.3%
Debt / equity
0.6×
Interest coverage
8.1×
Current ratio
0.9×
Free cash flow
$11.8B
Tangible book value
$27.5B
Cash & investments
$5.7B
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-08 | Sharma Mani | Grant | 1 | $179.75 |
| 2026-05-20 | Sharma Mani | Sell | 12K | $185.78 |
| 2026-05-06 | Sharma Mani | Grant | 1 | $186.28 |
| 2026-04-07 | Sharma Mani | Grant | 1 | $196.03 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07205666 ↗ | The Eplontersen Pregnancy and Lactation Outcomes Study Transthyretin Amyloidosis | — | Recruiting | 2035-12-30 |
| NCT06465810 ↗ | Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis Transthyretin Amyloidosis, ATTR-CM | — | Recruiting | 2031-12-29 |
| NCT06252753 ↗ | Observational Study Protocol: LIVER-R Hepatobiliary Cancers | — | Recruiting | 2030-12-30 |
| NCT07430306 ↗ | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus Systemic Lupus Erythematosus | PHASE3 | Recruiting | 2029-01-26 |
| NCT07647328 ↗ | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer ER-Positive HER2-Negative Breast Cancer | PHASE3 | Not Yet Recruiting | 2028-04-20 |
| NCT01838499 ↗ | Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa | PHASE2 | Terminated | 2014-10-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (1)
Named in the 10-K; linked when we track them.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-02-24 | 2025-12-31 | 0001104659-26-019130 ↗ |
| 20-F | 2025-02-18 | 2024-12-31 | 0001104659-25-014750 ↗ |
| 20-F | 2024-02-20 | 2023-12-31 | 0001104659-24-025553 ↗ |
| 20-F | 2023-02-21 | 2022-12-31 | 0001104659-23-023818 ↗ |
| 20-F | 2022-02-22 | 2021-12-31 | 0001104659-22-025720 ↗ |
| 20-F | 2021-02-16 | 2020-12-31 | 0001104659-21-022456 ↗ |
| 20-F | 2020-03-03 | 2019-12-31 | 0001104659-20-028557 ↗ |
| 20-F | 2019-03-05 | 2018-12-31 | 0001104659-19-012881 ↗ |